Latacomp (Timolol Maleate, Latanoprost)

• Latacomp, a combination antiglaucoma agent, is used to manage conditions characterized by elevated intra‑ocular pressure.
• Primary open‑angle glaucoma: lowers IOP to slow disease progression.
• Ocular hypertension: reduces IOP to prevent conversion to glaucoma.
• Glaucoma (any type): provides IOP reduction when pressure‑lowering therapy is required.

• Timolol maleate acts as a non‑selective β‑adrenergic blocker, decreasing aqueous humor production, while latanoprost, a prostaglandin F2α analogue, increases uveoscleral outflow by remodeling extracellular matrix. The combined effect results in a greater reduction of intra‑ocular pressure than either component alone.

Adverse reactions may occur with ocular use of Latacomp.

Common Side Effects

• Eye irritation or burning sensation.
• Blurred vision shortly after instillation.
• Redness of the conjunctiva.
• Itching or mild allergic response.
• Dry eye sensation.
• Foreign body feeling in the eye.

Serious or Rare Side Effects

• Severe allergic reaction with swelling or hives.
• Persistent eye pain or corneal edema.
• Sudden loss of vision.
• Unexpected increase in intra‑ocular pressure.
• Systemic beta‑blocker effects such as bradycardia or hypotension.
• Worsening of asthma or COPD symptoms.

• Use of Latacomp requires careful assessment of patient history and monitoring.
• Pregnancy: use only if the potential benefit justifies the potential risk to the fetus.
• Breastfeeding: caution advised; the drug may be excreted in breast milk.
• Systemic β‑blocker contraindications: avoid in patients with asthma, COPD, severe bradycardia, or heart block.
• Contact lens wearers: remove lenses before instilling drops and wait at least 15 minutes before reinserting.
• Monitor intra‑ocular pressure: assess response after initiation and adjust therapy as needed.
• Store at room temperature: keep in the original container, protect from light and moisture.

Latacomp may interact with other medications affecting ocular pressure or systemic β‑adrenergic activity.

Major Interactions (Avoid)

• Concomitant use of other non‑selective β‑blockers (e.g., propranolol) may cause additive systemic β‑blockade.
• Simultaneous administration of other prostaglandin analogs can increase risk of ocular inflammation.

Moderate Interactions (Monitor Closely)

• Topical or systemic adrenergic agonists (e.g., epinephrine) may diminish timolol's IOP‑lowering effect.
• Carbonic anhydrase inhibitors (e.g., dorzolamide) may produce additive IOP reduction; monitor pressure closely.
• Systemic antihypertensives may enhance timolol‑induced bradycardia.
• NSAID eye drops may interfere with latanoprost absorption.
• Anticholinergic agents may affect tear film stability, influencing tolerability.